Literature DB >> 10881203

Addiction and its reward process through polymorphisms of the D2 dopamine receptor gene: a review.

E P Noble1.   

Abstract

Since 1990, association studies have amassed strong evidence implicating the D(2) dopamine receptor (DRD2) gene in alcoholism. Specifically, the TaqI A minor (A1) allele of the DRD2 gene has been associated with alcoholism. The DRD2 gene has also been found to be involved in other substance use disorders including cocaine, nicotine and opioid dependence, and obesity. Beyond association studies, pharmacologic studies have shown reduced brain D(2) dopamine receptor numbers in A1(+) allele carriers (A1A1 and A1A2 genotypes) compared to A1(-) allele carriers (A2A2 genotype). Through a number of other approaches, different phenotypes have also been identified in subjects with the A1(+) and A1(-) alleles. These include metabolic, neurophysiological, neuropsychological, personality, stress and treatment studies. It is hypothesized that in an effort to compensate for deficiencies in the dopaminergic system, substance abusers may seek to stimulate the mesocorticolimbic circuits of the brain, long thought to be important in behavioral reward and reinforcement. In effect, one form of the DRD2 gene, the A1 allele, renders the dopaminergic system inefficient and rewards substance abuse that increases brain dopamine levels.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10881203     DOI: 10.1016/s0924-9338(00)00208-x

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  68 in total

1.  Behavioral screening for cocaine sensitivity in mutagenized zebrafish.

Authors:  T Darland; J E Dowling
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

Review 2.  Genetics of caffeine consumption and responses to caffeine.

Authors:  Amy Yang; Abraham A Palmer; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2010-06-09       Impact factor: 4.530

Review 3.  The prevention of gambling problems in youth: a conceptual framework.

Authors:  Laurie M Dickson; Jeffrey L Derevensky; Rina Gupta
Journal:  J Gambl Stud       Date:  2002

Review 4.  Gene-environment interplay in alcoholism and other substance abuse disorders: expressions of heritability and factors influencing vulnerability.

Authors:  Tomas Palomo; R M Kostrzewa; R J Beninger; T Archer
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 5.  Potential programming of dopaminergic circuits by early life stress.

Authors:  Ana-João Rodrigues; Pedro Leão; Miguel Carvalho; Osborne F X Almeida; Nuno Sousa
Journal:  Psychopharmacology (Berl)       Date:  2010-11-19       Impact factor: 4.530

Review 6.  Genetic Similarities between Compulsive Overeating and Addiction Phenotypes: A Case for "Food Addiction"?

Authors:  Nina Carlier; Victoria S Marshe; Jana Cmorejova; Caroline Davis; Daniel J Müller
Journal:  Curr Psychiatry Rep       Date:  2015-12       Impact factor: 5.285

Review 7.  Ebrii gignunt ebrios--One drunkard begets another: the genetics of alcohol dependence.

Authors:  David Ball
Journal:  Curr Psychiatry Rep       Date:  2005-04       Impact factor: 5.285

8.  Gene array profiling of large hypothalamic CNS regions in lactating and randomly cycling virgin mice.

Authors:  Stephen C Gammie; Nina S Hasen; Tarif A Awad; Anthony P Auger; Heather M Jessen; Jules B Panksepp; Anne M Bronikowski
Journal:  Brain Res Mol Brain Res       Date:  2005-10-03

9.  Detection of new single nucleotide polymorphisms by means of real time PCR.

Authors:  M Reuter; Y Küpper; A Schmitz; J P Breuer; U Wend; J Hennig
Journal:  J Genet       Date:  2005-12       Impact factor: 1.166

10.  The TaqIA RFLP is associated with attenuated intervention-induced body weight loss and increased carbohydrate intake in post-menopausal obese women.

Authors:  Jameason D Cameron; Marie-Ève Riou; Frédérique Tesson; Gary S Goldfield; Rémi Rabasa-Lhoret; Martin Brochu; Éric Doucet
Journal:  Appetite       Date:  2012-09-29       Impact factor: 3.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.